Switzerland
· Delayed Price · Currency is CHF Siegfried Holding AG Company Description
Siegfried Holding AG, together with its subsidiaries, provides contract development and manufacturing of active pharmaceutical ingredients (API) and finished dosage forms to the pharmaceutical industry worldwide.
It offers pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production services.
The company develops and produces APIs and intermediates, as well as finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products.
In addition, it provides APIs and controlled substances focusing on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition; exclusive synthesis services comprising process and chemical development, analytical development, pilot manufacturing and scale-up, and commercial manufacturing; and viral vector manufacturing solutions.
Further, the company licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for products.
Siegfried Holding AG was founded in 1873 and is headquartered in Zofingen, Switzerland.
| Country | Switzerland |
| Founded | 1873 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,070 |
| CEO | Marcel Imwinkelried |
Contact Details
Address: Untere Bruehlstrasse 4 Zofingen, 4800 Switzerland | |
| Phone | 41 62 746 1111 |
| Website | siegfried.ch |
Stock Details
| Ticker Symbol | SFZN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0014284498 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marcel Imwinkelried | Chief Executive Officer |
| Dr. Reto Suter Ph.D. | Chief Financial Officer |
| Dr. Jurgen Roos Ph.D. | Chief Scientific Officer |
| Dr. Luca Dalla Torre | General Counsel and Secretary |
| Peter Stierli | Head of Corporate Communications |
| Irene Wosgien | Chief Human Resources Officer |
| Marianne Spane | Chief Business Officer of Drug Substances and Drug Products |
| Enno Schweinberger Ph.D. | Head Global Quality Management DS - Zofingen |
| Daniel Nieper | Chief Strategy Officer |
| Beatrice Harder | Head Regulatory Affairs - Site Zofingen |